Erratum: Pegloticase (Nature Reviews Drug Discovery (2011) 10 (17-18) DOI: 10.1038/nrd3349);Pegloticase

Nature Reviews Drug Discovery

Volumn 10, Issue 1, 2011, Pages 17-18

  Schlesinger, Naomi ^a   Yasothan, Uma ^b   Kirkpatrick, Peter ^c  

^a ROBERT WOOD JOHNSON UNIVERSITY HOSPITAL   (United States)

^b IQVIA   (United States)

^c Nature Reviews Drug Discovery   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; CORTICOSTEROID; FEBUXOSTAT; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PEGLOTICASE; PLACEBO; URIC ACID;

ARTICLE; DISEASE SEVERITY; DRUG ACTIVITY; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; GOUT; HUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; TREATMENT INDICATION; URIC ACID BLOOD LEVEL;

EID: 78650835490     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd3384     Document Type: Erratum

References (15)

1. Richette, P. & Bardin, T. Gout. Lancet 375, 318-328 (2010).
2. Palmer, D. G., Highton, J. & Hessian, P. A. Development of the gout tophus. An hypothesis. Am. J. Clin. Pathol. 91, 190-195 (1989).
3. Burns, C. M. & Wortmann, R. L. Gout therapeutics: new drugs for an old disease. Lancet 16 Aug 2010 (doi:10.1016/S0140?6736(10)60665?4).
4. Zhang, W. et al. EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann. Rheum. Dis. 65, 1312-1324 (2006).
5. Pascual, E. et al. Febuxostat. Nature Rev. Drug Discov. 8, 191-192 (2008).
6. Sundy, J. S. et al. Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout. Arthritis Rheum. 56, 1021-1028 (2007).
7. Sundy, J. S. et al. Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study. Arthritis Rheum. 58, 2882-2891 (2008).
8. US Food and Drug Administration. FDA labelling information - Krystexxa (pegloticase). FDA website [online], http://www.accessdata.fda.gov/drugsatfda- docs/label/2010/125293s0000lbl.pdf (2010).
9. Thiele, R. G. & Schlesinger, N. Ultrasonography shows active inflammation in clinically unaffected joints in chronic tophaceous gout. Arthritis Rheum. 60, S565 (2009).
10. Mandel, D. R. et al. Use of pegloticase in chronic gout refractory to conventional therapy is associated with significant clinical benefit: tender joint and swollen joint counts and patient global assessment (Health Assessment Questionnaire). Arthritis Rheum. 62, S166 (2010).
11. Schlesinger, N. et al. Efficacy of canakinumab (ACZ885), a fully human anti-interleukin (IL)-1beta monoclonal antibody, in the prevention of flares in gout patients initiating allopurinol therapy. Arthritis Rheum. 62, S2087 (2010)
12. Terkeltaub, R. et al. Evaluation of rilonacept for prevention of gout flares during initiation of urate- lowering therapy: results of a phase 3, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 62, S152 (2010).
13. Baert, F. et al. Influence of immunogenicity on the long? term efficacy of infliximab in Crohn's disease. N. Engl. J. Med. 348, 601-608 (2003). IMS MIDAS (2010).
14. Richter, S. & Ekas, L. Collins Stewart Report on Savient Pharmaceuticals. (Collins Stewart, 5 Nov 2010).
15. Werher, C. Summer Street Report on Savient Pharmaceuticals. (Summer Street, 8 Nov 2010).